골다공증 : 주요 7개국의 의약품 시장 예측 및 시장 분석

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Osteoporosis market through 2033.

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, predisposing a person to bone fragility and susceptibility to fracture. Common sites of fracture include the spine, hip, distal forearm, and proximal humerus. Such fractures are a major cause of morbidity in the general population and a patient's recovery can be slow, with many requiring full-time care.

Major drivers of growth in the osteoporosis market during the forecast period include the following -

• The increased use of Evenity across the 7MM, which will be accelerated by growing physician familiarity and clinical experience following recent launch
• The rising use of anabolic therapies, which are typically more expensive than anti-resorptive agents, in particular low-cost bisphosphonates
• An increase in the number of people with osteoporosis, in line with the growth of the global aging population

Major barriers to growth in the osteoporosis market during the forecast period will include the following -

• High cost of anabolic therapies and dual-action Evenity compared to affordable bisphosphonates, which have established long-term safety and efficacy profiles
• Loss of patent protection and/or market exclusivity for some products during the forecast period, and the subsequent launches of biosimilars and generics; this includes the expected launch of denosumab biosimilars in 2025 and 2027 across the 7MM, which will take substantial market share from marketed Prolia/Pralia
• Low patient compliance with many osteoporosis therapies due to adverse side effects, frequent administration leading to lifestyle disruption, the discomfort of regular subcutaneous or intravenous injections, as well as patients missing treatment appointments, especially due to other medical complications in older patients

Scope

• Overview of osteoporosis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized osteoporosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the osteoporosis therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for osteoporosis treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global osteoporosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM osteoporosis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM osteoporosis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Osteoporosis: Executive Summary

• 1.1 The osteoporosis market will show steady growth during the forecast period, reaching sales of $17.9B in 2033
• 1.2 Biosimilars and generics are forecast to take substantial market share from originator drugs during the forecast period
• 1.3 Poor compliance presents a significant unmet need in the osteoporosis landscape
• 1.4 Improved long-term safety profiles are necessary for future pipeline osteoporosis therapies
• 1.5 Entera Bio's oral teriparatide is projected to enter the US market during the forecast period
• 1.6 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related Reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification
• 3.3 Prognosis

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
• 4.5 Sources
• 4.6 Forecast assumptions and methods.
  • 4.6.1 7MM
• 4.7 Forecast assumptions and methods: total prevalent cases of osteoporosis.
  • 4.7.1 US
  • 4.7.2 France, Germany, Italy, Spain, and UK
  • 4.7.3 Japan
• 4.8 Forecast assumptions and methods: diagnosed prevalent cases of osteoporosis.
  • 4.8.1 US
  • 4.8.2 France
  • 4.8.3 Germany
  • 4.8.4 Italy, Spain, and UK
  • 4.8.5 Japan
• 4.9 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of primary osteoporosis and secondary osteoporosis.
  • 4.9.1 7MM
• 4.10 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of type 1 and type 2 osteoporosis.
  • 4.10.1 7MM
• 4.11 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use
  • 4.11.1 7MM
• 4.12 Forecast assumptions and methods: total prevalent cases of osteopenia.
  • 4.12.1 US
  • 4.12.2 France and Germany
  • 4.12.3 Italy
  • 4.12.4 Spain
  • 4.12.5 UK
  • 4.12.6 Japan
• 4.13 Forecast assumptions and methods: diagnosed prevalent cases of osteopenia.
  • 4.13.1 7MM
• 4.14 Epidemiological forecast for osteoporosis (2023-33)
  • 4.14.1 Total prevalent cases of osteoporosis
• 4.15 Age-specific total prevalent cases of osteoporosis
• 4.16 Sex-specific total prevalent cases of osteoporosis
• 4.17 Total prevalent cases of osteoporosis by primary and secondary osteoporosis
• 4.18 Total prevalent cases of primary osteoporosis by type
• 4.19 Total prevalent cases of osteoporosis secondary to glucocorticoid use
• 4.20 Diagnosed prevalent cases of osteoporosis.
• 4.21 Age-specific diagnosed prevalent cases of osteoporosis
• 4.22 Sex-specific diagnosed prevalent cases of osteoporosis
• 4.23 Diagnosed prevalent cases of osteoporosis by primary and secondary osteoporosis.
• 4.24 Diagnosed prevalent cases of primary osteoporosis by type.
  • 4.24.1 Diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
• 4.25 Discussion
• 4.26 Epidemiological forecast insight
• 4.27 COVID-19 impact.
• 4.28 Limitations of the analysis
• 4.29 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
  • 5.1.1 Diagnosis of osteoporosis
  • 5.1.2 Treatment guidelines for osteoporosis
  • 5.1.3 Treatment among osteoporosis subtypes
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Improved diagnosis and treatment rates
• 7.3 Higher rates of compliance with osteoporosis treatment
• 7.4 Better safety profiles for long-term drug treatment

8 R&D Strategies

• 8.1 Overview
• 8.2 Focus on the development of biosimilars
• 8.3 Investigating the Wnt signaling pathway for future osteoporosis therapies
• 8.4 Clinical trials design
  • 8.4.1 Improvements in patient representation in osteoporosis clinical trials
  • 8.4.2 Novel biomarkers for osteoporosis assessment in clinical trials

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key Events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and Barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting Methodology
• 13.4 Primary Research - KOLs Interviewed for This Report
  • 13.4.1 Elizabeth Shane, MD
• 13.5 Primary Research - Prescriber Survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Vice President of Disease Intelligence and Epidemiology
  • 13.6.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us